New vaccines for mammalian allergy using molecular approaches

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Van Hage, Marianne ^a   Pauli, Gabrielle ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Allergen specific immunotherapy; Fel d 1; Mammalian allergens; Recombinant allergens; T cell peptides; Vaccines

Indexed keywords

ALLERGEN; ALLERVAX CAT; CALCITRIOL; CAT ALLERGEN FEL D 1; HYBRID PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; IMMUNOMODULATING AGENT; PEPTIDE; PEPTIDE VACCINE; RECOMBINANT ALLERGEN; T CELL PEPTIDE; TOLEROMUNE CAT; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC DISEASE; CAT; DENDRITIC CELL; HUMAN; IMMUNOREACTIVITY; IMMUNOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; VACCINE PRODUCTION;

EID: 84897932423     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00081     Document Type: Short Survey

References (46)

1. Jacobsen L, Niggeman B, Dreborg S, Ferdousi HA, Halken S, Koivikko A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10 year follow-up on the PAT study. Allergy (2007) 62:943-8. doi: 10.1111/j.1398-9995.2007.01451.x
2. Wickman M, Asarnoj A, Tillander H, Andersson N, Bergström A, Kull I, et al. Childhood-to-adolescence evolution of IgE antibodies to pollens and plant foods in the BAMSE cohort. J Allergy Clin Immunol (2014) 133:580-2.e8. doi:10.1016/j.jaci.2013.09.009
3. Hedlin G, Graff-Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow K, et al. Immunotherapy with cat-and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol (1991) 87:955-64. doi:10.1016/0091-6749(91)90417-M
4. Curin M, Reininger R, Swoboda I, Focke M, Valenta R, Spitzauer S. Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog allergens. Int Arch Allergy Immunol (2011) 154:258-63. doi:10.1159/000321113
5. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 172:3252-9.
6. Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir Med (2009) 103:800-12. doi:10.1016/j.rmed.2009.01.008
7. Kiel MA, Röder E, van Wijk RG, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol (2013) 132:353-60. doi:10.1016/j.jaci.2013.03.013
8. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol (2013) 131:1288.e-96.e. doi:10.1016/j.jaci.2013.01.049
9. Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Nieberberger V, Swoboda I, et al. From allergen genes to allergy vaccines. Annu Rev Immunol (2010) 28:211-41. doi:10.1146/annurev-immunol-030409-101218
10. Thomas WR. The advent of recombinant allergens and allergen cloning. J Allergy Clin Immunol (2011) 127:855-9. doi:10.1016/j.jaci.2010.12.1084
11. Valenta R, Campana R, Marth K, van Hage M. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med (2012) 272:144-57. doi:10.1111/j.1365-2796.2012.02556.x
12. Pauli G, Larsen TH, Rak SZ, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol (2008) 122:951-60. doi:10.1016/j.jaci.2008.09.017
13. Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol (2012) 12:556-63. doi:10.1097/ACI.0b013e328357ca53
14. Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy (2010) 40(3):385-97. doi:10.1111/j.1365-2222.2009.03443.x
15. Marth K, Breyer I, Focke-Tejkl M, Blatt K, Shamji MH, Layhadi J, et al. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol (2013) 190:3068-78. doi:10.4049/jimmunol.1202441
16. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med (2005) 11:446-9. doi:10.1038/nm1219
17. Martinez-Gomez JM, Johansen P, Rose H, Steiner M, Senti G, Rhyner C, et al. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy (2009) 64:172-8. doi:10.1111/j.1398-9995.2008.01812.x
18. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M. Amb a 1-linked CpG oligo-deoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol (2002) 109:455-62. doi:10.1067/mai.2002.122156
19. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol (2004) 113:235-41. doi:10.1016/j.jaci.2003.11.001
20. Neimert-Andersson T, Thunberg S, Swendin L, Wiedermann U, Jacobsson-Ekman G, Dahlen SE, et al. Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy (2008) 53:518-26. doi:10.1111/j.1398-9995.2008.01644.x
21. Taher YA, van Esch BC, Hofman GA, Henricks PA, van Oosterhout A. 1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-β. J Immunol (2008) 180:5211-21.
22. Grundström J, Neimert-Andersson T, Kemi C, Nilsson OB, Saarne T, Andersson M, et al. Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy. Int Arch Allergy Immunol (2012) 157:136-46. doi:10.1159/000327546
23. Johansen P, von Moos S, Mohanan D, Kündig TM, Senti G. New routes for allergen immunotherapy. Hum Vaccin Immunother (2012) 8:1525-33. doi:10.4161/hv.21948
24. Oldfield WL, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 360:47-53. doi:10.1016/S0140-6736(02)09332-7
25. Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol (2011) 127:89-97. doi:10.1016/j.jaci.2010.11.029
26. Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol (2013) 131:103-9. doi:10.1016/j.jaci.2012.07.028
27. Ferrari E, Breda D, Longhi R, Vangelista L, Nakaie CR, Elviri L, et al. In search of a vaccine for mouse allergy: significant reduction of Mus m 1 allergenicity by structure-guided single-point mutations. Int Arch Allergy Immunol (2012) 157:226-37. doi:10.1159/000327551
28. Saarne T, Kaiser L, Grönlund H, Rasool O, Gafvelin G, van Hage-Hamsten M. Rational design of hypoallergens applied to the major cat allergen Fel d 1. Clin Exp Allergy (2005) 35:657-63. doi:10.1111/j.1365-2222.2005.02234.x
29. Nilsson OB, Adedoyin J, Rhyner C, Neimert-Andersson T, Grundström J, Berndt KD, et al. In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity. PLoS One (2011) 6:e24558. doi:10.1371/journal.pone.0024558
30. Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S, et al. Displaying Fel d 1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med (2009) 206:1941-55. doi:10.1084/jem.20090199
31. Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent PM, et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol (2011) 127:1562-70. doi:10.1016/j.jaci.2011.02.004
32. Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol (2012) 129:1290-6. doi:10.1016/j.jaci.2012.02.026
33. Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, et al. 1,25-Dihydroxyvitamin D3 an IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol (2009) 183:5458-67. doi:10.4049/jimmunol.0803217
34. Thunberg S, Neimert-Andersson T, Cheng Q, Wermeling F, Bergström U, Swedin L, et al. Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice. Allergy (2009) 64:919-26. doi:10.1111/j.1398-9995.2008.01905.x
35. Moldaver D, Larché M. Immunotherapy with peptides. Allergy (2011) 66:784-91. doi:10.1111/j.1398-9995.2011.02610.x
36. Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naïve and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d 1. Proc Natl Acad Sci U S A (1993) 90:7608-12. doi:10.1073/pnas.90.16.7608
37. Norman PS, Ohman JL, Long AA, Creticos PS, Gefter MA, Shaked Z, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med (1996) 154:1623-8. doi:10.1164/ajrccm.154.6.8970345
38. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol (1999) 93:222-31. doi:10.1006/clim.1999.4795
39. Immonen A, Farci S, Taivainen A, Partanen J, Pouvelle-Moratille S, Närvänen A, et al. T cell epitope-containing peptides of the major dog allergen Can f 1 as candidates for allergen immunotherapy. J Immunol (2005) 15(175):3614-20.
40. Kinnunen T, Jutila K, Kwok WW, Rytkönen-Nissinen M, Immonen A, Saarelainen S, et al. Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy. J Allergy Clin Immunol (2007) 119:965-72. doi:10.1016/j.jaci.2007.01.011
41. Immonen A, Kinnunen T, Sirven P, Taivainen A, Houitte D, Peräsaari J, et al. The major horse allergen Equ c 1 contains one immunodominant region for T cell epitopes. Clin Exp Allergy (2007) 37:939-47. doi:10.1111/j.1365-2222.2007.02722.x
42. Saarne T, Neimert-Andersson T, Grönlund H, Jutel M, Gafvelin G, van Hage M. Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy. Allergy (2011) 66:255-63. doi:10.1111/j.1398-9995.2010.02468.x
43. Milich DR. T-and B-cell recognition of hepatitis B viral antigens. Immunol Today (1988) 9:380-6. doi:10.1016/0167-5699(88)91239-X
44. Terada T, Zhang K, Belperio J, Londhe V, Saxon A. A chimeric human-cat Fcgamma-Fel d1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1, the major cat allergen. Clin Immunol (2006) 120:45-56. doi:10.1016/j.clim.2005.12.010
45. Martínez-Gómez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kündig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol (2009) 150(1):59-65. doi:10.1159/000210381
46. Nilsson OB, van Hage M, Gronlund H. Mammalian-derived respiratory allergens-implications for diagnosis and therapy of individuals allergic to furry animals. Methods (2014) 66:86-95. doi:10.1016/j.ymeth.2013.09.002